Pneumocystis Jirovecii Pneumonia
Original Editor - Donald John Auson Top Contributors - Donald John Auson, Kim Jackson, Lucinda hampton and Nupur Smit Shah
This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (Template:12/Template:FEBRUARY/Template:2020)
Introduction[edit | edit source]
Pneumocystis JIrovecii Pneumonia (PJP) was previously called as Pneumocystis Carinii Pneumonia (PCP), it is one of the most common opportunistic fungal infection in immuno-compromised conditions such as haematological malignancy, congenital immunodeficiency, organ transplantation, immunosuppressive therapy, under medication and predominantly in HIV. [1]
Epidemiology[edit | edit source]
Etiology[edit | edit source]
The pathogen responsible for PJP is Pneumocystis Jirovecii, an organism classified as a fungus.
Pathophysiology[edit | edit source]
Signs and Symptoms[edit | edit source]
Diagnostic Procedures[edit | edit source]
Differential Diagnosis[edit | edit source]
Prognosis[edit | edit source]
Pharmacological Management[edit | edit source]
Physiotherapy Intervention[edit | edit source]
Resources[edit | edit source]
References[edit | edit source]
- ↑ Ricciardi A, Gentilotti E, Coppola L, Maffongelli G, Cerva C, Malagnino V, et al. Infectious disease ward admission positively influences P. jiroveci pneumonia (PJP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients. PLoS ONE. 2017;12(5):e0176881.
